We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.

This study has been terminated.
(Teh Priincipal investigator responsible for the trial no longer employed at the study site.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00256100
First Posted: November 21, 2005
Last Update Posted: April 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Melbourne Health
  Purpose
The purpose of this project is to assess the safety and effectiveness of fondaparinux, a new drug to prevent blood clotting in the continuous dialysis machine used in intensive care patients who have kidney failure.

Condition Intervention
Renal Failure Drug: Fondaparinux Sodium

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Assessment of the Safety and Efficacy of Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Renal Failure.

Resource links provided by NLM:


Further study details as provided by Melbourne Health:

Primary Outcome Measures:
  • The study will evaluate the duration of filter patency using fondaparinux as an anticoagulant in haemofiltration and compare this to the current standard haemofilter anticoagulant, enoxaparin. [ Time Frame: Duration of the haemofilter life ]

Secondary Outcome Measures:
  • To assess the incidence of complications, primary bleeding with fondaparinux compared to enoxaparin in this setting. [ Time Frame: Until hospital discharge ]

Enrollment: 20
Study Start Date: June 2004
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: One
Enoxaparin Sodium (Clexane ) is to be used in the control arm of the study
Drug: Fondaparinux Sodium
The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation
Other Name: Arixtra
Active Comparator: Two
Fondaparinux will be used as the anticoagulant in the sencond arm of the study
Drug: Fondaparinux Sodium
The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation
Other Name: Arixtra

Detailed Description:

The study hypothesis is that when used as an anticoagulant in haemofiltration, fondaparinux prolongs the filter life when compared to enoxaparin.

Fondaparinux is the first compound of a new class of synthetic oligosaccharides with antithrombotic effects. It represents the active portion of the natural heparin molecule.

The null hypothesis is that there is no difference in filter life when using fondaparinux or enoxaparin as anticoagulation for haemofiltration.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adult patients (18 years or over) admitted to the ICU and expected to stay for more than 48 hours.
  2. Patients who require continuous renal replacement therapy.
  3. Patients who consent or if the patient is not competent, the next of kin who consent to inclusion in the study. .

Exclusion Criteria:

  1. Patients aged less than 18 years of age.
  2. Patients who are pregnant
  3. Patients with a contraindication to anticoagulation for pre existing bleeding diathesis
  4. Patients or next of kin who do not consent to study inclusion. -
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00256100


Locations
Australia, Victoria
The Royal Melbourne Hospital Intensive Care Unit Grattan Street
Parkville, Victoria, Australia, 3050
Sponsors and Collaborators
Melbourne Health
Investigators
Principal Investigator: John F Cade Melbourne Health
  More Information

ClinicalTrials.gov Identifier: NCT00256100     History of Changes
Other Study ID Numbers: 2004.066
First Submitted: November 17, 2005
First Posted: November 21, 2005
Last Update Posted: April 12, 2017
Last Verified: April 2015

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Fondaparinux
PENTA
Anticoagulants
Factor Xa Inhibitors
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Fibrinolytic Agents
Fibrin Modulating Agents